A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

This study has been terminated.
(FDA imposed Clinical Hold after a number of patients taking Encenicline (EVP-6124) in Alzheimer Disease trials reported serious gastrointestinal side effects)
FORUM Pharmaceuticals Inc
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
A. Eden Evins, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
First received: November 23, 2011
Last updated: September 18, 2015
Last verified: September 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2015
  Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)